Kira Biotech

Kira Biotech, established in 2017 and based in Brisbane, Australia, specializes in the development of innovative immunomodulatory compounds to treat immune system disorders. Its flagship product, KB312, is a first-in-class, selective monoclonal antibody designed to target and deplete activated immune cells, aiming to restore balance and induce immune tolerance. Led by renowned US-based rheumatologist and immunologist Dr. Dan Baker, Kira Biotech is advancing KB312 through preclinical and phase 1 clinical trials, backed by venture capital funding.